TWI809015B - 用於治療乳癌及前列腺癌之組合物 - Google Patents

用於治療乳癌及前列腺癌之組合物 Download PDF

Info

Publication number
TWI809015B
TWI809015B TW107144106A TW107144106A TWI809015B TW I809015 B TWI809015 B TW I809015B TW 107144106 A TW107144106 A TW 107144106A TW 107144106 A TW107144106 A TW 107144106A TW I809015 B TWI809015 B TW I809015B
Authority
TW
Taiwan
Prior art keywords
dexamethasone
amount
composition
treated
study
Prior art date
Application number
TW107144106A
Other languages
English (en)
Chinese (zh)
Other versions
TW201938157A (zh
Inventor
貝艾 艾德溫娜 巴斯金
喬 伊斯納
伊莉莎白 烏斯登
Original Assignee
澳大利亞商肯比醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 澳大利亞商肯比醫療公司 filed Critical 澳大利亞商肯比醫療公司
Publication of TW201938157A publication Critical patent/TW201938157A/zh
Application granted granted Critical
Publication of TWI809015B publication Critical patent/TWI809015B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107144106A 2017-12-07 2018-12-07 用於治療乳癌及前列腺癌之組合物 TWI809015B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595918P 2017-12-07 2017-12-07
US62/595,918 2017-12-07

Publications (2)

Publication Number Publication Date
TW201938157A TW201938157A (zh) 2019-10-01
TWI809015B true TWI809015B (zh) 2023-07-21

Family

ID=66750338

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107144106A TWI809015B (zh) 2017-12-07 2018-12-07 用於治療乳癌及前列腺癌之組合物

Country Status (8)

Country Link
US (2) US20210292410A1 (https=)
EP (1) EP3720427A4 (https=)
JP (1) JP7437576B2 (https=)
CN (1) CN111698985B (https=)
AU (1) AU2018380155B2 (https=)
CA (1) CA3084997A1 (https=)
TW (1) TWI809015B (https=)
WO (1) WO2019113301A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358983B2 (en) 2016-10-28 2025-07-15 Incyte Corporation Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof
US12357615B2 (en) 2018-10-11 2025-07-15 Kembi Therapeutics Pty Ltd Compositions for the treatment of brain tumors
CA3158748A1 (en) * 2019-10-25 2021-04-29 Garvan Institute Of Medical Research Methods of treating cancer using androgen receptor antagonists
US12150776B2 (en) * 2021-04-26 2024-11-26 Wisconsin Alumni Research Foundation & AIQ Solutions, Inc. System and method for monitoring multiple lesions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI600647B (zh) * 2010-11-13 2017-10-01 英諾庫因製藥公司 金屬酶抑制劑化合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
DK0431519T3 (da) 1989-12-04 1994-07-04 Searle & Co System til transdermal indgivelse af albuterol
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
CA2755976C (en) 2009-03-23 2020-04-07 Ambit Biosciences Corporation Methods of treatment using combination therapy
EP2751117A4 (en) * 2011-08-30 2015-06-24 Innocrin Pharmaceuticals Inc METALLOENZYMHEMMERVERBINDUNGEN
US20150005265A1 (en) * 2011-12-22 2015-01-01 Susan Stewart Methods and compositions for combination therapy using p13k/mtor inhibitores
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI600647B (zh) * 2010-11-13 2017-10-01 英諾庫因製藥公司 金屬酶抑制劑化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
期刊 Lorente et al. Tumour Responses Following a Steroid Switch From Prednisone to Dexamethasone in Castration-Resistant Prostate Cancer Patients Progressing on Abiraterone British Journal of Cancer 111 2014 2248-2253;期刊 Stein et al. Androgen synthesis inhibitors in the treatment of castration‑resistant prostate cancer Asian Journal of Andrology 16 2014 387-400 *
期刊 Stein et al. Androgen synthesis inhibitors in the treatment of castration‑resistant prostate cancer Asian Journal of Andrology 16 2014 387-400

Also Published As

Publication number Publication date
JP2021505669A (ja) 2021-02-18
CN111698985B (zh) 2023-10-31
WO2019113301A1 (en) 2019-06-13
US20210154209A1 (en) 2021-05-27
AU2018380155B2 (en) 2024-07-04
CA3084997A1 (en) 2019-06-13
EP3720427A4 (en) 2021-09-15
JP7437576B2 (ja) 2024-02-26
CN111698985A (zh) 2020-09-22
AU2018380155A1 (en) 2020-07-02
US20210292410A1 (en) 2021-09-23
US11980626B2 (en) 2024-05-14
TW201938157A (zh) 2019-10-01
EP3720427A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
TWI809015B (zh) 用於治療乳癌及前列腺癌之組合物
JP6564372B2 (ja) バルドキソロンメチルまたはその類似体を使用して内皮機能障害を処置および予防する方法
JP6846392B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
JP2023525571A (ja) 肝障害の併用処置
RU2753607C2 (ru) Способы лечения острого повреждения почек
EP2461814A2 (en) Treatment of prostate cancer
CA3059562A1 (en) Combination therapy for prostate cancer
WO2014118195A1 (en) Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
EP3908279B1 (en) Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
CN111033634A (zh) 用于治疗纤维化疾病的化合物及其药物组合物
CN117327019A (zh) 一种局部作用的雄激素受体拮抗剂的应用
US20050070565A1 (en) Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders
CA2898450A1 (en) Isometheptene isomer
JP2002523461A (ja) 神経変性疾患の治療方法
US20250381179A1 (en) Chroman-based compounds for treating cancer
US12589090B2 (en) Compounds and methods for the treatment of degenerative disorders
WO2024023696A1 (en) Dosing regimen for a nlrp3 inhibitor
WO2012119010A9 (en) Materials for inhibiting aromatase and method of using the same to diagnose, treat and monitor breast cancer
EP3265075B1 (en) Roneparstat combined therapy of multiple myeloma
CA3230285A1 (en) Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof